Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MANBA | O00462 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.33 |
| ▸ | AGL | P35573 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15266072 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL7432236 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL15265936 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL4585300 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL3069911 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL9880695 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL4172279 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL15265566 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL10075956 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL22090238 | 1.00 | MANBA (0.44) | MANBALMNATHRBHIF1ASLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115552026-A | Enzymatic method for preparing CMP-Neu5Ac | 马克斯·普朗克科学促进学会 | 2022-12-30 | — | — | CN | disclosed |
| US-20170159105-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170159105-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9574220-B2 | Enzyme assays on a droplet actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9574220-B2 | Enzyme assays on a droplet actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2516669-B1 | ENZYME ASSAYS ON A DROPLET ACTUATOR | ADVANCED LIQUID LOGIC INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150184219-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150184219-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9012165-B2 | Assay for B-galactosidase activity | ADVANCED LIQUID LOGIC, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140141460-A1 | Method of Conducting an Assay | ADVANCED LIQUID LOGIC, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130130936-A1 | Method of Conducting an Assay | ADVANCED LIQUID LOGIC, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8394641-B2 | Method of hydrolyzing an enzymatic substrate | ADVANCED LIQUID LOGIC INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394641-B2 | Method of hydrolyzing an enzymatic substrate | ADVANCED LIQUID LOGIC INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120136147-A1 | Method of hydrolyzing an enzymatic substrate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-31 | — | — | US | disclosed |
| US-20120136147-A1 | Method of hydrolyzing an enzymatic substrate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-31 | — | — | US | disclosed |
| US-8093062-B2 | Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-10 | — | — | US | disclosed |
| WO-2011084703-A2 | ENZYME ASSAYS ON A DROPLET ACTUATOR | ADVANCED LIQUID LOGIC, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110118132-A1 | Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil | ADVANCED LIQUID LOGIC, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150184219-A1 | Enzyme Assays on a Droplet Actuator | IDE, UCHL3, UGDH | MANBA 260/4885LMNA 3024/4885THRB 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.